FIELD: medicine.
SUBSTANCE: method of preventing tuberculosis by oral intermittent administration of inactivated mycobacteria, with the interval between doses not exceeding 5 days, the number of doses of not less than 5. Technical result: tolerance response to infection by the tubercle bacillus is characterized by an increased proportion of regulatory T cells (Treg); providing a protective response due to control of induction of the disease when infected with mycobacteria and preventing recurrence of the treated active phase of tuberculosis.
EFFECT: inactivated bacteria can be used according to the aforementioned treatment regimen to control the progression of the infection from a latent state to active tuberculosis.
15 cl, 9 dwg, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HBHA-DETECTION OF TUBERCULOSIS AND MYCOBACTERIUM TUBERCULOSIS INFECTION | 2005 |
|
RU2426128C2 |
| VACCINES OF RECOMBINANT INTRACELLULAR PATHOGENS AND USES THEREOF | 2001 |
|
RU2266132C2 |
| PREPARATIONS, CONTAINING HUMAN ANTIBODIES APPLIED IN TREATMENT OF MICROBACTERIAL INFECTIONS | 2003 |
|
RU2350352C2 |
| ANTITUBERCULOUS VACCINE | 2007 |
|
RU2443773C2 |
| IMMUNOTHERAPEUTIC AGENT FOR PRIMARY PREVENTION OF TUBERCULOSIS | 2009 |
|
RU2544125C2 |
| COMPOSITIONS FOR USE AS A PREVENTIVE AGENT FOR PATIENTS WITH A RISK OF TB INFECTION OR AS A SECONDARY AGENT FOR THE TREATMENT OF PATIENTS WITH TB INFECTION | 2019 |
|
RU2778094C2 |
| COMPOSITIONS AND METHODS FOR TREATING ACTIVE MYCOBACTERIUM TUBERCULOSIS INFECTION | 2013 |
|
RU2659149C2 |
| LIPOSOME FORMULATION SUITABLE FOR TREATING OR PREVENTING TUBERCULOSIS | 2012 |
|
RU2648842C2 |
| ANTITUBERCULOSIS REMEDY | 2017 |
|
RU2756208C2 |
| PREVENTIVE ANTI-TUBERCULOSIS VACCINE | 2007 |
|
RU2526910C2 |
